AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory ...

AstraZeneca has started to pull its Covid-19 vaccine from global markets because of low demand, the pharmaceutical giant said. The decision closes the chapter on a shot that was widely used in the ...

But the vaccine has not generated revenue for AstraZeneca since April 2023, the company said. “As multiple, variant Covid-19 vaccines have … been developed, there is a surplus of available ...

AstraZeneca, which is withdrawing its COVID-19 vaccine, says independent estimates show that it saved over 6.5 million lives in the first year of its use.

The pharmaceutical giant AstraZeneca on Tuesday said it is withdrawing its COVID-19 vaccine worldwide due to low demand and following reports that the vaccine caused rare side effects.

AstraZeneca Wednesday said it was pulling its Vaxzevria COVID-19 vaccine pictured here from sale globally for commercial reasons. The company has admitted in Britain's High Court that in rare ...

AstraZeneca is withdrawing its COVID-19 vaccine from worldwide circulation and marketing authorizations. The British-Swedish company recently acknowledged side effects such as blood clots and low ...